Publications by authors named "Hu Xichun"

Claim this Profile
E
Efficacy and safety of ARX788 for individuals with HER2-positive breast cancer and brain metastases (ACE-Breast-06): a single-arm, phase 2 trial in China.
Ting Li, Mingxi Lin, Biyun Wang, Mingchuan Zhao, Jun Cao, Xichun Hu

EClinicalMedicine· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and genomic characteristics of HER2-ultralow breast cancer and implications for T-DXd therapy.
Juan Jin, Tiantian Liu, Mengyuan Cai, Mingchuan Zhao, Duanchen Guo, Xichun Hu

Precis Clin Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer.
Veronique Dieras, Giuseppe Curigliano, Miguel Martin, Florence Lerebours, Junji Tsurutani, Xichun Hu

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The methyltransferase-like proteins as core regulators of nucleic acid modifications and post-translation modification of proteins in disease pathogenesis and therapeutic implications.
Shenyuqi Wu, Duancheng Guo, Xichun Hu, Mengdi Yang

Biomark Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurogenic inducers inhibit the proliferation of pancreatic cancer by promoting tumor cell transdifferentiation.
Duancheng Guo, Saimeng Shi, Longyun Ye, Mengdi Yang, Wenxia Peng, Xichun Hu

J Exp Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of nomograms of outcomes for first-line platinum-based chemotherapy for metastatic triple-negative breast cancer: patient-level analysis of five prospective clinical trials in China.
Chengcheng Gong, Ting Li, Yifan Chen, Jian Zhang, Yannan Zhao, Xichun Hu

Ther Adv Med Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Entrectinib in Asian patients with ROS1 fusion-positive non-small cell lung cancer: updated efficacy and safety analysis.
Shun Lu, Yun Fan, Xiaorong Dong, Yan Yu, Juan Li, Xichun Hu

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of bireociclib for the treatment of advanced solid tumors as monotherapy and in combination with endocrine therapy: a multicenter, open-label, phase 1 clinical trial.
Jiayu Wang, Tao Sun, Zhongsheng Tong, Xichun Hu, Wei Li

BMC Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I open-label study to assess the pharmacokinetics, safety, and tolerability of capivasertib alone or in combination with paclitaxel in Chinese patients with advanced solid tumors.
Jian Zhang, Xiaojun Liu, Yiqun Du, Yuxin Mu, Yanchun Meng, Xichun Hu

BMC Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical Trial.
Zhonghua Tao, Jian Zhang, Qiufan Zheng, Yongsheng Wang, Li Cai, Xichun Hu

JAMA Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.
Mario Campone, Michelino De Laurentiis, Komal Jhaveri, Xichun Hu, Sylvain Ladoire

N Engl J Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MYC amplification sensitizes TNBC to CHK1 inhibitors.
Bin Li, Tiantian Liu, Mingchuan Zhao, Duancheng Guo, Wenxia Peng, Xichun Hu

Cell Signal· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential regulatory role of the m A-lncRNA axis in breast cancer: molecular mechanisms and therapeutic implications.
Di Chen, Jinyan Wang, Xichun Hu, Shu Liu

Acta Biochim Biophys Sin (Shanghai)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial.
Jian Zhang, Yanchun Meng, Biyun Wang, Xinhong Wu, Hongmei Zheng, Xichun Hu

PLoS Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancements in Diagnostics and Therapeutics for Cancer of Unknown Primary in the Era of Precision Medicine.
Ting Zhao, Xiaowei Zhang, Xin Liu, Qifeng Wang, Xichun Hu

MedComm (2020)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
8
8MW0511, a novel, long-acting granulocyte-colony stimulating factor fusion protein for the prevention of chemotherapy-induced neutropenia: final results from the phase III clinical trial.
Biyun Wang, Xiuchun Chen, Hongtao Li, Jing Sun, Xinjian Jia, Xichun Hu

Breast Cancer Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.
Xichun Hu, Qingyuan Zhang, Tao Sun, Huihua Xiong, Wei Li

Nat Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated efficacy and safety of HLX02 versus reference trastuzumab in metastatic HER2-positive breast cancer: A randomized phase III equivalence trial.
Binghe Xu, Qingyuan Zhang, Tao Sun, Wei Li, Yue'e Teng, Xichun Hu

Breast· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I dose-escalation and expansion study of RMX1002, a selective E-type prostanoid receptor 4 antagonist, as monotherapy and in combination with anti-PD-1 antibody in advanced solid tumors.
Dan Liu, Jifang Gong, Jian Zhang, Yongqian Shu, Hao Wu, Xichun Hu

Invest New Drugs· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors.
Mingchuan Zhao, Xichun Hu, Pengpeng Zhuang, Aiping Zeng, Yan Yu

J Bone Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of the Pharmacokinetics and Safety of Ipatasertib, an Akt Inhibitor in Chinese Patients With Locally Advanced or Metastatic Solid Tumors.
Jian Zhang, Rujiao Liu, Dhruvit Sutaria, Rucha Sane, Minhao Fan, Xichun Hu

Clin Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Xichun Hu, Qingyuan Zhang, Leiping Wang, Jian Zhang, Quchang Ouyang

Signal Transduct Target Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Ferroptosis-related genes as prognostic markers for survival and immunotherapy in triple-negative breast cancer: analysis of public databases and a single institution.
Yizhao Xie, Zhonghua Tao, Biyun Wang, Yannan Zhao, Xinyu Chen, Xichun Hu

Ther Adv Med Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathological characteristics, evolution, and treatment outcomes of hormone receptor-negative/HER2-low metastatic breast cancer: a pooled analysis of individual patient data from three prospective clinical trials.
Shihui Hu, Yannan Zhao, Yizhao Xie, Shuhui You, Xichun Hu

Front Endocrinol (Lausanne)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported quality of life in Asian patients with ER+/HER2- advanced breast cancer treated with palbociclib plus letrozole in the PALOMA-4 trial.
Binghe Xu, Xichun Hu, Wei Li, Tao Sun, Kunwei Shen

Chin Med J (Engl)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis